Stanford University
Showing 121-130 of 2,397 Results
-
Michael Baiocchi
Associate Professor of Epidemiology and Population Health and, by courtesy, of Statistics and of Medicine (Stanford Prevention Research Center)
On Partial Leave from 01/01/2026 To 12/01/2026BioProfessor Baiocchi is a PhD statistician in Stanford University's Epidemiology and Population Health Department. He thinks a lot about behavioral interventions and how to rigorously evaluate if and how they work. Methodologically, his work focuses on creating statistically rigorous methods for causal inference that are transparent and easy to critique. He designed -- and was the principle investigator for -- two large randomized studies of interventions to prevent sexual assault in the settlements of Nairobi, Kenya.
Professor Baiocchi is an interventional statistician (i.e., grounded in both the creation and evaluation of interventions). The unifying idea in his research is that he brings rigorous, quantitative approaches to bear upon messy, real-world questions to better people's lives. -
Matthew C. Baker, MD MS
Assistant Professor of Medicine (Immunology and Rheumatology)
BioDr. Baker is the Associate Division Chief in the Division of Immunology and Rheumatology at Stanford University and an internationally recognized expert in IgG4-related disease, as well as the Co-Founder and Co-Director of the Stanford Multidisciplinary Sarcoidosis Program. He received his bachelor's degree from Pomona College, his medical degree from Harvard Medical School, and his master's degree in Epidemiology and Clinical Research from Stanford University. He completed his Internal Medicine residency at the Massachusetts General Hospital and his Rheumatology fellowship at Stanford University. Dr. Baker's clinical research program is focused on clinical trials, epidemiological studies, and bench-to-bedside translational research. He has designed and led investigator-initiated and industry sponsored clinical trials in IgG4-related disease, sarcoidosis, Sjogren's disease, and rheumatoid arthritis. His epidemiological work aims to better understand disease mechanisms and identify novel drug targets, with a particular interest in repurposing existing drugs for the treatment of osteoarthritis.
